TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the end of the six-month soft lock-up period of shares and the end of the lock-up of convertible bonds following the transaction announced on April 18, 2023. As part […]
continue readingResults of the 2023 Annual General Meeting of shareholders and resumption of the liquidity contract
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the results of its 2023 annual general meeting of shareholders (AGM), which took place on June 29, 2023, at 01:30 p.m. CEST. Shareholders representing a total of 39.86% of […]
continue readingTME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month mark further surpasses the expected survival in patients resistant to chemotherapy with incomplete surgical tumor removal Survival data will improve further as time progresses and patients remain on study Continued strong performance improves NOX-A12 profile for partnering […]
continue readingTME Pharma Announces Convocation of the 2023 Annual General Meeting of Shareholders
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 01.30 p.m. CEST on June 29, 2023, at the offices of Freshfields Bruckhaus Deringer […]
continue readingTME Pharma publishes audited annual report 2022
Financial visibility extended into December 2023 Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumab Survival data continue to improve with 83% of patients alive after one year 15-month survival data expected in mid-2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused […]
continue readingTME Pharma Announces Successful €2 Million Financing and the End of the Convertible Bond Program with a Lock-Up of New Shares and Lock-Up of Bond Conversions Extending Financial Runway into December 2023
€2 million new cash secured Termination of the convertible bond agreement by TME Pharma Lock-up of all new shares issued and all outstanding convertible bonds for a period of 6 months to align investors and support company through next clinical results TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel […]
continue readingTME Pharma Publishes Unaudited Financial Results for Fiscal Year 2022
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the publication of unaudited financial results for the fiscal year 2022 in order to allow the company to complete a transaction before publication of the annual report 2022. The […]
continue readingTME Pharma announces convocation of an extraordinary general meeting of shareholders
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an extraordinary general meeting of shareholders (the EGM) of the company is convened at 01.30 p.m. CET on January 30, 2023, at the offices of Freshfields Bruckhaus […]
continue readingTME Pharma announces the resignation of its chief financial officer Bryan Jennings
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the company’s Chief Financial Officer (CFO), Bryan Jennings, has resigned for personal reasons. He will remain in his role through December 31, 2022, in order to ensure […]
continue readingTME Pharma reports H1 2022 Financial results and provides business update
Promising top-line results warrant focus of the clinical development on NOX-A12 combination therapies in brain cancer NOX-A12 + bevacizumab 12-month survival data in glioblastoma expected in April 2023 Cash runway into June 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the […]
continue reading